Compare Firy Inc. (FIRY) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Merck & Co., Inc. — how do they compare? Firy Inc. trades at $10.21 (market cap $163.57M), while Merck & Co., Inc. trades at $130.46 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 1974.7× Firy Inc.'s market cap, and Merck & Co., Inc. pays a 2.6% dividend while Firy Inc. pays none. Which is the better fit depends on your goals.
| FIRY | MRK | |
|---|---|---|
Market Cap | $163.57M | $323.00B |
Sector | Consumer Cyclical | Health |
52-Week High | $12.45 | $131.84 |
52-Week Low | $2.28 | $77.60 |
Enterprise Value | $107.24M | $369.77B |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY stock trades at $10.45, up 4.5% today, with a bullish technical signal from moving averages. The company shows improving revenue trends ($104.5M in 2025, projected to $112M in 2026) but continues to post significant losses (-$70.4M net income). Recent developments include a successful $719M legal victory and corporate rebranding from Skillz Inc. Analyst sentiment is mixed with 20% buy, 60% hold, and 20% sell ratings.
While technical indicators suggest near-term upside potential, fundamental challenges persist with negative profitability metrics and cash burn. The stock presents speculative appeal based on legal wins and revenue stabilization, but requires careful risk management given ongoing losses and negative cash flow trends.
MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
